SIS
RDHL

Sound Income Strategies’s Redhill Biopharma RDHL Stock Holding History

Sound Income Strategies’s Portfolio RDHL Stock Details RDHL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-1
Closed -$3.66K – 1002
2021
Q1 		$3.66K Hold
1
– – ﹤0.01% 671
2020
Q4 		$4K Hold
1
– – ﹤0.01% 630
2020
Q3 		$5K Buy
+1
New +$8.2K ﹤0.01% 544

Other funds holding RDHL

DGI
Disciplined Growth Investors Minneapolis, Minnesota $4.89B AUM 33.85% 1-Year Est. Return
II
Ibex Investors Denver, Colorado $152M AUM 19.17% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
DCM
DAFNA Capital Management Los Angeles, California $440M AUM 109.12% 1-Year Est. Return
GS
Gagnon Securities New York $433M AUM 29.08% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
ACM
ACT Capital Management Wayne, Pennsylvania $153M AUM

Sound Income Strategies's RDHL Position: Q2 2021 in Review

Sound Income Strategies sold out of Redhill Biopharma (RDHL) in Q2 2021, closing a stake of 1 share — an estimated $3.66K sold.

Sound Income Strategies first reported a position in RDHL in Q3 2020 and held it in 3 quarters. The position peaked at $5K in Q3 2020. 48 funds tracked by Wall St. Rank hold RDHL as of Q2 2021.

  • Sound Income Strategies reported no remaining Redhill Biopharma position as of Q2 2021 after selling out during the quarter.
  • Sound Income Strategies sold 1 Redhill Biopharma share in Q2 2021, an estimated $3.66K.
  • Sound Income Strategies first reported a position in Redhill Biopharma in Q3 2020 and held it in 3 quarters.
  • Sound Income Strategies's Redhill Biopharma position peaked at $5K in Q3 2020.
  • 48 funds tracked by Wall St. Rank held Redhill Biopharma as of Q2 2021.

Based on Sound Income Strategies's 13F filing for Q2 2021, filed 13 Jul 2021.